Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	56.52B
Revenue (ttm)	18.58B
Net Income (ttm)	5.07B
Shares Out	265.35M
EPS (ttm)	19.23
PE Ratio	11.08
Forward PE	10.41
Dividend	5.73 (2.69%)
Ex-Dividend Date	Aug 5, 2024

Volume	546,722
Average Volume	2,056,105
Open	214.00
Previous Close	214.50
Day's Range	212.00 - 215.00
52-Week Range	172.50 - 332.50
Beta	0.13
RSI	41.06
Earnings Date	May 9, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.